Key Points to Consider When Evaluating Andexxa for Formulary Addition
Crossref DOI link: https://doi.org/10.1007/s12028-019-00866-6
Published Online: 2019-10-22
Published Print: 2020-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Peled, Harry http://orcid.org/0000-0003-0016-3574
Dau, Nhu Quyen
Lau, Helen
Text and Data Mining valid from 2019-10-22
Version of Record valid from 2019-10-22
Article History
First Online: 22 October 2019
Conflict of interest
: All authors declare that they have no conflict of interest.
Free to read: This content has been made available to all.